目的 观察磷酸奥司他韦颗粒联合单磷酸阿糖腺苷治疗小儿手足口病的临床疗效。方法 选择2013年8月-2015年6月在首都儿科研究所附属儿童医院感染科收治的小儿手足口病患者64例。所有患者随机分为对照组和治疗组，每组各32例。对照组静脉注射或肌肉注射单磷酸阿糖腺苷治疗，5～10 mg/kg加入到0.9%氯化钠溶液2 mL中，1次/d；治疗组在对照组基础上口服磷酸奥司他韦颗粒，体质量≤15 kg：30 mg/次，15 kg < 体质量≤23 kg：45 mg/次，23 kg < 体质量≤40 kg：60 mg/次，体质量>40 kg：75 mg/次，2次/d。两组患者均连续治疗10 d。观察两组的临床疗效，比较两组患者的发热消退时间、皮疹疱疹消退时间及痊愈时间。结果 治疗后，对照组和治疗组的总有效率分别为87.5%、96.9%，两组比较差异有统计学意义（P<0.05）。治疗后，治疗组患者的发热消退时间、皮疹疱疹消退时间及痊愈时间均显著短于对照组，两组比较差异具有统计学意义（P<0.05）。结论 磷酸奥司他韦颗粒联合单磷酸阿糖腺苷治疗小儿手足口病具有较好的临床疗效，能缓解临床症状，安全性较好，具有一定的临床推广应用价值。

Objective To observe the clinical effect of Oseltamivir Phosphate Granules combined with vidarabine monophosphate in treatment of children with hand foot and mouth disease. Methods Children (64 cases) with hand foot and mouth disease in Department of Infectious Diseases, Children's Hospital Affiliated to Capital Institute of Pediatrics from August 2013 to June 2015 were randomly divided into the control and treatment groups, and each group had 32 cases. Children in the control group were iv or im administered with Vidarabine Monophosphate for injection, 5-10 mg/kg added to normal saline 2 mL, once daily. Children in the treatment group were po administered with Oseltamivir Phosphate Granules on the basis of the control group, body weight ≤15 kg:30 mg/time, 15 kg < body weight≤23 kg:45 mg/time, 23 kg < body weight≤40 kg:60 mg/time, body weight >40 kg:75 mg/time, twice daily. Children in two groups were treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and fever subsided time, rash herpes subsided time, and recovery time in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 87.5% and 96.9%, respectively, and there was difference between two groups (P<0.05). After treatment, fever subsided time, rash herpes subsided time, and recovery time in the treatment group were shorter than those in the control group, with significantly difference between two groups (P<0.05). Conclusion Oseltamivir Phosphate Granules combined with vidarabine monophosphate has clinical curative effect in treatment of children with hand foot and mouth disease, and can relieve clinical symptoms with good safety, which has a certain clinical application value.